What is Global Intravenous Immunoglobulin (IVIg) Market?
The Global Intravenous Immunoglobulin (IVIg) Market is a vast and complex field that involves the production, distribution, and use of intravenous immunoglobulin, a blood product used in the treatment of various immune deficiencies and autoimmune diseases. This market is a crucial component of the global healthcare industry, providing life-saving treatment options for patients around the world. IVIg is a sterile solution of antibodies, or immunoglobulin (Ig) extracted from the plasma of thousands of blood donors. It is administered intravenously and is used to treat diseases of the immune system, infections, and a variety of other medical conditions.
IVIg Liquid, IVIg Powder in the Global Intravenous Immunoglobulin (IVIg) Market:
The Global Intravenous Immunoglobulin (IVIg) Market is divided into two main product types: IVIg Liquid and IVIg Powder. IVIg Liquid is a ready-to-use, sterile solution of human immunoglobulin for intravenous administration. IVIg Powder, on the other hand, is a lyophilized (freeze-dried) powder that needs to be reconstituted with a suitable diluent before it can be administered intravenously. Both types of IVIg have their own advantages and disadvantages, and the choice between the two often depends on the specific needs and circumstances of the patient.
Immunodeficiency, Autoimmune Disease, Acute Infection in the Global Intravenous Immunoglobulin (IVIg) Market:
The Global Intravenous Immunoglobulin (IVIg) Market plays a crucial role in the treatment of various medical conditions. These include Immunodeficiency, Autoimmune Disease, and Acute Infection. Immunodeficiency refers to a state where the immune system's ability to fight infectious disease is compromised or entirely absent. IVIg is often used as a replacement therapy for patients with primary and secondary immunodeficiencies. Autoimmune diseases, on the other hand, are conditions in which the body's immune system mistakenly attacks its own cells. IVIg is used in the treatment of various autoimmune diseases due to its immunomodulatory effects. Lastly, IVIg is also used in the treatment of acute infections, providing a boost to the immune system to help it fight off the infection.
Global Intravenous Immunoglobulin (IVIg) Market Outlook:
The future of the Global Intravenous Immunoglobulin (IVIg) Market looks promising. As per the market outlook, the market was valued at US$ 10310 million in 2022. It is projected to reach a value of US$ 15470 million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 5.9% during the forecast period from 2023 to 2029. The market is dominated by the top four manufacturers who collectively hold a market share of more than 65%. Geographically, North America holds the largest share of the market, accounting for about 45% of the total market.
| Report Metric | Details |
| Report Name | Intravenous Immunoglobulin (IVIg) Market |
| Accounted market size in 2023 | US$ 10970 million |
| Forecasted market size in 2029 | US$ 15470 million |
| CAGR | 5.9 |
| Base Year | 2023 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Segment by Region |
|
| By Company | Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
